Movatterモバイル変換

[0]ホーム

Jump to content

Conatumumab

Edit links

From Wikipedia, the free encyclopedia

Monoclonal antibody

Pharmaceutical compound

Conatumumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	TRAIL-R2 (CD262)
Clinical data
Other names	anti-TRAIL receptor 2 monoclonal antibody, AMG-655
ATC code	none
Identifiers
CAS Number	896731-82-1^N
ChemSpider	none
UNII	1P48L61KM0
KEGG	D09329^Y
Chemical and physical data
Formula	C₆₄₆₆H₁₀₀₀₆N₁₇₃₀O₂₀₂₄S₄₀
Molar mass	145645.66 g·mol⁻¹
^NY (what is this?) (verify)

Conatumumab (originally AMG-655) is amonoclonal antibody developed for the treatment of cancer. It is a fully human monoclonal agonist antibody directed against the extracellular domain of humanTRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2, death receptor 5) with potentialantineoplastic activity.^[1]^[2] Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activatingcaspase cascades and inducing tumor cellapoptosis. TR-2 is expressed by a variety of solid tumors and cancers ofhematopoietic origin.^[3]^[4]

The drug was developed byAmgen Inc. In 2008,Takeda licensed the drug from Amgen for development in Japan, but discontinued development in 2011.

References

[edit]

^Rosevear HM, Lightfoot AJ, Griffith TS (June 2010). "Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancer".Current Opinion in Investigational Drugs.11 (6). London, England:688–98.PMID 20496264.
^Bajaj M, Heath EI (November 2011). "Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults".Expert Opinion on Biological Therapy.11 (11):1519–24.doi:10.1517/14712598.2011.610788.PMID 21877997.S2CID 28520935.
^Statement On A Nonproprietary Name Adopted By The USAN Council – Conatumumab,American Medical Association.
^National Cancer Institute: Definition of conatumomab

Monoclonal antibodies for tumors

Tumor

Human	Adecatumumab^§ Amivantamab Ascrinvacumab^§ Atezolizumab (+hyaluronidase) Balstilimab^† Botensilimab Cixutumumab^§ Conatumumab^§ Cosibelimab Daratumumab Drozitumab^§ Duligotumab^§ Dusigitumab^§ Enfortumab vedotin Enoticumab^§ Figitumumab^§ Flanvotumab^§ Ganitumab^† Glembatumumab vedotin^† Intetumumab^§ Ipilimumab Iratumumab^§ Istiratumab Icrucumab^§ Lexatumumab^§ Linvoseltamab Lucatumumab^§ Mapatumumab^§ Narnatumab^§ Necitumumab Nesvacumab^§ Nivolumab^# (+hyaluronidase,+relatlimab) Ofatumumab Olaratumab^† Panitumumab Patritumab^§ Pembrolizumab^# Pritumumab^§ Radretumab^§ Ramucirumab Rilotumumab^† Robatumumab^§ Seribantumab^§ Sugemalimab Tarextumab^§ Tisotumab vedotin Teprotumumab^† Tovetumab^§ Vantictumab^§ Votumumab^§ Zalutumumab^†
Mouse	Abagovomab Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox Moxetumomab pasudotox Naptumomab estafenatox Oregovomab Pemtumomab^† Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Nofetumomab merpentan Pintumomab Tenatumomab Tositumomab
Chimeric	Amatuximab^§ Bavituximab^§ Brentuximab vedotin Carotuximab^† Cetuximab Derlotuximab biotin^§ Dinutuximab Ecromeximab^§ Ensituximab^§ Futuximab^§ Girentuximab^† Indatuximab ravtansine^§ Isatuximab Loncastuximab tesirine Margetuximab Mirvetuximab soravtansine Rituximab^# Siltuximab Ublituximab Zolbetuximab
Humanized	Abituzumab^§ Alemtuzumab Axatilimab Belantamab mafodotin Bevacizumab Bivatuzumab mertansine^§ Brontictuzumab^§ Cantuzumab mertansine^§ Cantuzumab ravtansine^§ Cirmtuzumab Citatuzumab bogatox^§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab^§ Demcizumab^§ Dalotuzumab^§ Datopotamab deruxtecan Denintuzumab mafodotin^§ Elotuzumab Emactuzumab Emibetuzumab^§ Enoblituzumab^§ Epcoritamab Etaracizumab^§ Farletuzumab^§ Ficlatuzumab^§ Flotetuzumab^§ Gemtuzumab ozogamicin Glofitamab Imgatuzumab^§ Inotuzumab ozogamicin Labetuzumab^§ Lifastuzumab vedotin^§ Lintuzumab^§ Lorvotuzumab mertansine^§ Lumretuzumab^§ Matuzumab^§ Milatuzumab^§ Naxitamab Nimotuzumab^† Obinutuzumab Ocaratuzumab^§ Odronextamab Otlertuzumab^§ Onartuzumab^§ Oportuzumab monatox^† Parsatuzumab^§ Pertuzumab Pinatuzumab vedotin^§ Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine^† Sacituzumab govitecan Sibrotuzumab^§ Simtuzumab^§ Sofituzumab vedotin^§ Tacatuzumab tetraxetan^§ Tigatuzumab^§ Trastuzumab^# (+deruxtecan /+emtansine) Tucotuzumab celmoleukin^§ Vandortuzumab vedotin^§ Vanucizumab^§ Veltuzumab^§ Vorsetuzumab mafodotin^§ Zenocutuzumab
Rat/mouse hybrid	Catumaxomab Ertumaxomab^§
Chimeric + humanized	Depatuxizumab mafodotin^† Duvortuxizumab Ontuxizumab^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Thismonoclonal antibody–related article is astub. You can help Wikipedia byexpanding it.

Thisantineoplastic orimmunomodulatory drug article is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Conatumumab&oldid=1184660731"

Categories:

Hidden categories:

[8]ページ先頭